I've been meaning to post this for weeks because it's one of the most dramatic quality-of-life improvements I've experienced. I had moderate-to-severe obstructive sleep apnea (OSA) diagnosed via polysomnography 3 years ago. I've been on CPAP every night since, titrated to 12 cm H2O.

Started tirzepatide 15 mg in February 2024 for weight loss and T2DM. After losing 65 lbs over 10 months, my sleep medicine doctor ordered a repeat sleep study. Results:

My AHI went from 34.2 (severe) to 7.1 (mild). My sleep doctor said I no longer meet criteria for CPAP therapy (threshold is AHI >15, or >5 with symptoms). I've been off CPAP for 6 weeks and sleeping better than I have in years. My Epworth score of 4 indicates no excessive daytime sleepiness.

Weight: 298 → 233 lbs. BMI: 41.6 → 32.5. Neck circumference: 18.5 → 16 inches.

This is consistent with the STEP-HFpEF program data and the recently completed SURMOUNT-OSA trials. Let me provide the clinical trial context.

In SURMOUNT-OSA, tirzepatide reduced AHI by approximately 55-63% in patients with moderate-to-severe OSA and obesity. The AHI reduction was significantly greater than placebo and sufficient to shift many patients from severe to mild or from moderate to normal.^[1]

Your AHI reduction from 34.2 to 7.1 represents a 79% decrease, which exceeds the trial mean — likely because your weight loss (22%) was also above the trial average.

The mechanisms are primarily anatomical but also functional:

• Fat reduction around the upper airway: Pharyngeal fat pad volume correlates strongly with OSA severity. Your 2.5-inch neck circumference reduction reflects this.
• Reduced abdominal mass: Less diaphragmatic compression improves functional residual capacity and reduces the tendency for airway collapse.
• Improved neuromuscular control: GLP-1 RAs may enhance genioglossus muscle responsiveness during sleep (preclinical data).
• Reduced fluid shift: Less fluid redistribution from legs to neck during recumbency in patients with lower body weight.

^[1] Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). N Engl J Med. 2024;391(14):1288-1298.

The cardiometabolic implications of OSA resolution are enormous and often underappreciated. OSA is an independent risk factor for:

• Hypertension (intermittent hypoxia drives sympathetic activation)
• Atrial fibrillation (prevalence 2-4x higher in OSA)
• Pulmonary hypertension
• Insulin resistance (nocturnal hypoxemia impairs glucose metabolism)
• Systemic inflammation (hsCRP elevation)

By resolving OSA, the OP is simultaneously removing a major driver of cardiovascular and metabolic risk. The combination of weight loss + OSA resolution + the direct metabolic effects of tirzepatide creates a synergistic improvement that's greater than the sum of its parts.

I often tell patients that treating sleep apnea is one of the highest-impact things you can do for cardiovascular health, right alongside blood pressure and lipid management.

Thank you both. The sleep quality improvement is honestly the thing I'm most grateful for. Before semaglutide (I was on CPAP), I was functional but never felt truly rested. Without CPAP now, I'm waking up naturally, dreaming again (I hadn't dreamed in years — apparently I was barely reaching REM sleep), and my energy is completely different.

My wife says I no longer snore. After 15 years of earplugs and separate bedrooms on bad nights, this is relationship-altering.

The STEP-HFpEF trial also provided relevant sleep apnea data. While primarily a heart failure trial, many enrolled patients had concurrent OSA. Key cardiac and sleep outcomes:^[1]

The KCCQ improvement reflects overall functional capacity, which is directly impacted by sleep quality. Patients with HFpEF and concurrent OSA saw the largest functional improvements, suggesting that treating both conditions simultaneously yields outsized benefit.

^[1] Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF). N Engl J Med. 2023;389(12):1069-1084.